SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and Viking Therapeutics, Inc.

Biotech SG&A Trends: Ascendis vs. Viking

__timestampAscendis Pharma A/SViking Therapeutics, Inc.
Wednesday, January 1, 201462740001244910
Thursday, January 1, 201594150005029636
Friday, January 1, 2016115040004846776
Sunday, January 1, 2017134820005329003
Monday, January 1, 2018250570007121000
Tuesday, January 1, 2019484730009128000
Wednesday, January 1, 20207666900010731000
Friday, January 1, 202116018000010701000
Saturday, January 1, 202222122700016121000
Sunday, January 1, 202326441000037021000
Monday, January 1, 2024284545000
Loading chart...

Data in motion

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational expenses is crucial for success. Ascendis Pharma A/S and Viking Therapeutics, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. Ascendis Pharma's SG&A expenses have surged by over 4,100% from 2014 to 2023, reflecting its aggressive expansion and investment in growth. In contrast, Viking Therapeutics has maintained a more conservative approach, with a 2,900% increase over the same period.

Key Insights

  • Ascendis Pharma A/S: From 2014 to 2023, the company saw a significant rise in SG&A expenses, peaking at $264 million in 2023.
  • Viking Therapeutics, Inc.: Despite a steady increase, their expenses reached only $37 million in 2023.
    This analysis highlights the strategic differences in managing operational costs, offering valuable insights for investors and industry analysts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025